incretin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-05 and is reviewed periodically as new material appears.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
== Predicted properties == Other than nuclear properties, no properties of meitnerium or its compounds have been measured; this is due to its extremely limited and expensive production and the fact that meitnerium and its parents decay very quickly. Properties of meitnerium metal remain unknown and only predictions are available.
== GLP-1, GIP, and glucagon receptor triple agonists == Following the discovery of GLP-1/GIP and GLP-1/glucagon dual agonists, it was hoped that a triple agonist would provide additive or synergistic metabolic benefits. A clinical trial of the triple agonist retatrutide found an average 24.2% weight reduction in the highest dosage group after 24 weeks. Another clinical trial of triple agonist UBT-251 also found an average weight reduction of 19.7% after 24 weeks.
Visualizing bacterial cell wall structures. Studying bacterial cell wall growth. Monitoring bacterial cell wall turnover. Quantifying bacterial cell wall growth activity. Assaying the anti-cell wall ability of antibiotics. Screening new anti-cell wall antibiotics. Tracking transpeptidase activity in vitro.
Dingane's army then attacked and massacred a group of 250 Voortrekker men, women and children camped nearby. The site of this massacre is today called Weenen, (Dutch for "to weep"). The remaining Voortrekkers elected a new leader, Andries Pretorius, who led a successful defence of the Voortrekker position from the Zulu forces and Dingane at the Battle of Blood River on 16 December 1838, when 15,000 Zulu impis (warriors) attacked a group of 470 Voortrekker settlers led by Pretorius.
Sources: en.wikipedia.org
==== ASTA pungency unit ==== The ASTA (American Spice Trade Association) pungency unit is based on a scientific method of measuring chili pepper "heat". The technique utilizes high-performance liquid chromatography to identify and measure the concentrations of the various compounds that produce a heat sensation. Scoville units are roughly 1⁄15 the size of pungency units while measuring capsaicin, so a rough conversion is to multiply pungency by 15 to obtain Scoville heat units.
=== Medication === Overall, pharmaceuticals have limited benefit for treating anorexia. However, olanzapine, an antipsychotic, has been shown to result in a modest but statistically significant increase in body weight in AN patients, in addition to a decrease in obsessive thoughts. While the effectiveness of antidepressants in treating anorexia has not been well established, fluoxetine, an SSRI, can also be used during treatment. Metreleptin is undergoing research for its potential benefit in the treatment of anorexia nervosa. It is hypothesized that the gradual loss of body fat mass, and the ensuing low leptin levels, influence the psychological components of the disorder. It was shown that short-term metreleptin treatment of patients with anorexia nervosa had rapid on-set of beneficial cognitive, emotional, and behavioral effects. Among other things, depression, drive for activity, repetitive thoughts of food, inner restlessness, and weight phobia decreased rapidly. Whether metreleptin (or another leptin analogue) is a suitable treatment for anorexia nervosa remains to be seen.
The OMX Nordic 40 (OMXN40) is a stock market index for the pan-regional (virtual) Nasdaq Nordic. It is a price return and capitalization-weighted index. The base date for the index is 28 December 2001, with a base value of 1000. The OMX Nordic 40 was launched on 2 October 2006 and consists of the 40 largest and most traded stocks from the four stock exchanges operated by Nasdaq Nordic: Nasdaq Stockholm, Nasdaq Copenhagen, Nasdaq Helsinki and Nasdaq Iceland (although no Icelandic companies are currently included). The free float market capitalization and turnover of the securities are calculated in Euro. The index is reconstituted and rebalanced semi-annually in June and December.
Sources: en.wikipedia.org
== Bibliography == Shapiro, Fred R.; Epstein, Joseph (2006). The Yale Book of Quotations. Yale University Press. ISBN 978-0-300-10798-2. Willmott, H. P. (2003). World War I. Dorling Kindersley. ISBN 978-0-7894-9627-0. OCLC 52541937.
== Misery Index == Bloomberg's Misery Index 2019 ranked Thailand as the world's "least miserable" economy. The index is calculated as the sum of a country's inflation and unemployment rates. In 2019, Bloomberg again took a swipe at Thai statistics: "Thailand again claimed the title of the 'least miserable' economy, though the government’s unique way of tallying unemployment makes it less noteworthy...." Singapore was ranked as the third "least miserable" and Malaysia, sixth. Bloomberg's Misery Index 2017 ranked Thailand 65 of 65 nations (65=least miserable, 1=most miserable). The index measures the unemployment rate coupled with the inflation rate. Bloomberg commented that "The least miserable country is once again Thailand—in large part due to its unique way of calculating employment..." Other ASEAN nations were ranked: Singapore, 64; Malaysia, 55; Vietnam, 54; Philippines, 37; Indonesia, 23. Bloomberg's Misery Index 2016 ranked Thailand 63 of 63 nations (63=least miserable, 1=most miserable). The index measures the unemployment rate coupled with the inflation rate.
=== Support of Alan L. Hart === Lawrence played a supportive role in the early career of physician and radiologist Alan L. Hart. Following Hart’s transition in 1917, she provided professional advocacy and a written recommendation that helped him secure a medical appointment at the Albuquerque Sanatorium.
== Protein structure == The monomer protein, consisting of 54 amino acid residues, is the smallest of the sweet proteins with a molecular weight of 6.5 kDa. The amino acid sequence of brazzein, adapted from the Swiss-Prot biological database of protein, is as follows: QDKCKKVYEN YPVSKCQLAN QCNYDCKLDK HARSGECFYD EKRNLQCICD YCEY The structure of brazzein was determined by proton nuclear magnetic resonance (NMR) at a pH of 5.2 and 22 °C. Brazzein has four evenly spaced disulfide bonds and no sulfhydryl groups. 3D analysis of brazzein showed one alpha-helix and three strands of anti-parallel beta sheet. This is not superficially similar to either of the other two sweet-tasting proteins, monellin and thaumatin. However, a recent 3D study shows that these three proteins possess similar "sweet fingers" believed to elicit the sweet taste. Residues 29–33 and 39–43, plus residue 36, as well as the C-terminus were found to be involved in the sweet taste of the protein. The charge of the protein also plays an important role in its interaction with the sweet taste receptor. Based on this knowledge a synthesised improved brazzein, called pGlu-1-brazzein, was reported to be twice as sweet as the natural counterpart.
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.